NeuVasQ is a spin-off company from the University of Brussels aiming to repair neurovascular function in a range of disorders by restoring the integrity of the blood-brain barrier.
The blood-brain barrier (BBB) regulates the exchange between the vascular system and central nervous system (CNS). Increased BBB permeability, due to age or injury, is involved in many neurological conditions through the leakage of harmful blood substances into the CNS. BBB dysfunction is a factor in many neurodegenerative disorders, such as Alzheimer’s, as well as multiple acute neurological conditions like stroke and epilepsy.
The company’s approach involves precisely targeting the pathways responsible for BBB formation, with the aim to restore lost functionality to the neurovasculature. NeuVasQ plans to further develop this targeted approach.
The company’s current focus is to identify the most promising indications for clinical trials, focusing on a range of neurodegenerative disorders and acute neurological disorders. As part of these exploratory studies, NeuVasQ will also consider various therapeutic modalities, including gene and mRNA therapy.
Originating from the Wyss Institute for Biologically Inspired Engineering at Harvard University, Unravel Biosciences has developed a vertically integrated computational platform to discover better drug …